Between the Lines
Between The Lines is designed to provide an in-depth video-based analysis of a specific published manuscript or article through a managed-care lens. Overall, the objective of this series is to present key data readouts along with the corresponding implications and impact on population health management strategies.
Ruxolitinib for Polycythemia Vera Intolerant or Resistant to Hydroxyurea
May 1st 2024Timothy Mok, PharmD, BCPS, BCOP, and Gabriela Hobbs, MD, review findings from the MAJIC-PV study and offer insights on the evolving treatment of patients with polycythemia vera who have hydroxyurea intolerance or resistance.
Read More
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper (SAPHYR Trial)
December 6th 2023The SAPHYR trial unveils serilumab's potential as a steroid-sparing option for refractory Polymyalgia Rheumatica, positively impacting patients, providers, and payers. Robert Spiera, MD, and Dana McCormick, RPh, discuss how Serilumab could reduce steroid-related side effects in these patients.
Read More
![Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fmhe%2F4d2792a54c4ea6fd0626f5704e12bc7056ec7525-1920x1080.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA")
